Skip to Content
Merck
  • Seminal Helicobacter pylori treatment improves sperm motility in infertile asthenozoospermic men.

Seminal Helicobacter pylori treatment improves sperm motility in infertile asthenozoospermic men.

Urology (2014-11-30)
Yehia El-Garem, Mohamed El-Sawy, Taymour Mostafa
ABSTRACT

To assess the effect of treatment of seminal Helicobacter pylori in infertile asthenozoospermic men. In all, 223 infertile asthenozoospermic men were consecutively selected. They were subjected to history taking, clinical examination, semen analysis, and estimation of H pylori IgA antibodies in their seminal fluid. Infertile men with high seminal H pylori IgA were subjected to triple drug treatment, omeprazole, 20 mg; tinidazole, 500 mg; and clarithromycin, 250 mg twice a day for 2 weeks. Semen analysis as well as H pylori IgA antibodies was estimated after 3 months. In all, 22 of 223 men (9.87%) demonstrated H pylori IgA antibodies in their seminal plasma. After treatment, mean seminal H pylori IgA levels demonstrated significant decrease (1.55 ± 0.4 vs 0.52 ± 0.26; 95% confidence interval, 0.83-1.21; P = .001) concomitant with improved progressive as well as nonprogressive sperm motility. H pylori IgA antibodies demonstrated significant negative correlation with progressive sperm motility, nonprogressive sperm motility, normal sperm morphology, and significant positive correlation with immotile sperm motility. H pylori treatment significantly improves sperm motility in infertile asthenozoospermic men with elevated seminal H pylori IgA.

MATERIALS
Product Number
Brand
Product Description

Omeprazole, European Pharmacopoeia (EP) Reference Standard
USP
Omeprazole, United States Pharmacopeia (USP) Reference Standard
Supelco
Omeprazole, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Clarithromycin Identity, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Omeprazole, solid
Omeprazole for peak identification, European Pharmacopoeia (EP) Reference Standard
Supelco
Omeprazole, analytical standard
USP
Clarithromycin, United States Pharmacopeia (USP) Reference Standard
Clarithromycin, European Pharmacopoeia (EP) Reference Standard
Supelco
Clarithromycin, Pharmaceutical Secondary Standard; Certified Reference Material
Clarithromycin for peak identification, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Clarithromycin, 96.0-102.0% (HPLC)
Supelco
Tinidazole, VETRANAL®, analytical standard
Sigma-Aldrich
Clarithromycin, ≥95% (HPLC)